Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.270 UNCHANGED
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value. 
Via The Motley Fool
Nvidia’s Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance
These Nvidia partner stocks stand to gain from the semiconductor's industry dominance, but they have plenty of upside of their own. 
Via InvestorPlace
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Both of these companies could soon set the standard in their fields. 
Via The Motley Fool
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Owns These 2 AI Stocks. Should You?
One looks like a solid option. The other one, not so much. 
Via The Motley Fool
Topics Artificial Intelligence
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
Recursion Pharm Stock Sees Relative Strength Rating Rise To 84
On Tuesday, Recursion Pharm stock had its Relative Strength (RS) Rating upgraded to 84, up from 78 a day earlier. 
Via Investor's Business Daily
Demystifying Recursion Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
Recursion Pharmaceuticals hopes to transform the healthcare industry with the help of AI. 
Via The Motley Fool
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in... 
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
You don't need to buy her picks, but it's worth understanding them. 
Via The Motley Fool
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
Dr. Hershberg is a current board member with over 25 years of experience as a physician, scientist, and entrepreneur 
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Stocks That Could 10x by 2035
These stocks are very promising, but it's important to consider the downside, too. 
Via The Motley Fool
Jim Cramer Offers His Take On Corning, Calls This Healthcare Stock A 'Terrific Spec'
Jim Cramer says Corning has "not been able to generate the kind of return that I've wanted"; calls Recursion a "terrific spec" 
Via Benzinga
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
What's the Difference Between Biotech Stocks and TechBio Stocks?
A few enterprising businesses are marketing themselves differently. 
Via The Motley Fool
Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
The Next Drug You Take May be Designed By A.I.
Three stocks could give investors a better way to tap into A.I.'s future potential inside drug development, an industry that is set to grow at 29.6% until 2030 
Via MarketBeat
Topics Artificial Intelligence
Recursion Pharmaceuticals Stock Surges 10% As Nvidia-Powered Supercomputer Completion Sparks Investor Optimism
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) made waves Monday afternoon not only with the announcement of its groundbreaking BioHive-2 supercomputer but also with a notable surge in its stock... 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024. 
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Is Buying This Under-the-Radar AI Stock
This company has massive upside potential, but that's not the whole story. 
Via The Motley Fool
Topics Artificial Intelligence
RXRX Stock Earnings: Recursion Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
RXRX stock results show that Recursion Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share,... 
Via Benzinga
Nvidia Favorite SoundHound AI Delivers Beat-And-Raise Report
SoundHound AI, which counts Nvidia as an investor, beat estimates for the first quarter and with its sales guidance. SOUN stock rose. 
Via Investor's Business Daily
Topics Artificial Intelligence
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback